You just read:

Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

News provided by

Trovagene, Inc.

Aug 26, 2019, 08:00 ET